The Washington Post @washingtonpost
Alzheimer’s drug that slows cognitive decline gets FDA approval. The drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness. https://t.co/tnHjelD9uG — PolitiTweet.org
